Development of Therapeutic Antibodies and Modulating the Characteristics of Therapeutic Antibodies to Maximize the Therapeutic Efficacy

다국어 초록 (Multilingual Abstract)

Monoclonal antibodies (mAb) have been used as therapeutic agents for various diseases, and immunoglobulin G (IgG) is mainly used among antibody isotypes due to its structural and functional properties. So far, regardless of the purpose of the therapeutic antibody, wildtype IgG has been mainly used, but recently, the engineered antibodies with various strategies according to the role of the therapeutic antibody have been used to maximize the therapeutic efficacy. In this review paper, first, the overall structural features and functional characteristics of antibody IgG, second, the old and new techniques for antibody discovery, and finally, several antibody engineering strategies for maximizing therapeutic efficacy according to the role of a therapeutic antibody will be introduced.

참고문헌 (Reference)

• 1 oder, E. T, "Yeast surface display for screening combinatorial polypeptide libraries" 15 : 553-557, 1997
• 2 Pincetic, A, "Type i and type II Fc receptors regulate innate and adaptive immunity" 15 : 707-716, 2014
• 3 Tabasinezhad, M, "Trends in therapeutic antibody affinity maturation: From in-vitro towards nextgeneration sequencing approaches" 212 : 106-113, 2019
• 4 Dahan, R, "Therapeutic activity of agonistic, human anti-CD40 monoclonal antibodies requires selective FcγR engagement" 29 : 820-831, 2016
• 5 Georgiou, G, "The promise and challenge of high-throughput sequencing of the antibody repertoire" 32 : 158-168, 2014
• 6 Van Roy, M, "The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis" 17 : 135-, 2015
• 7 Stapleton, N. M, "The multiple facets of FcRn in immunity" 268 : 253-268, 2015
• 8 Steinwand, M, "The influence of antibody fragment format on phage display based affinity maturation of IgG" 6 : 204-218, 2014
• 9 Rothe, C, "The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies" 376 : 1182-1200, 2008
• 10 Bolt, S, "The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties" 23 : 403-411, 1993
• 11 Teeling, J. L, "The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20" 177 : 362-371, 2006
• 12 Zhang, T, "The binding of an anti-PD-1 antibody to FcγRΙhas a profound impact on its biological functions" 67 : 1079-1090, 2018
• 13 Igawa, T, "Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation" 270 : 132-151, 2016
• 14 Liu, J, "Study of the interactions of a novel monoclonal antibody, mAb059c, with the hPD-1 receptor" 9 : 17830-, 2019
• 15 U.S. National Library of Medicine, "Study Record Detail, MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy"
• 16 U.S. National Library of Medicine, "Study Record Detail, Dual bNAb Treatment in Childre"
• 17 U.S. National Library of Medicine, "Study Record Detail, A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of PRV-3279 in Healthy Subjects (PREVAIL1)"
• 18 Bruhns, P, "Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses" 113 : 3716-3725, 2009
• 19 Eyer, K, "Single-cell deep phenotyping of IgG-secreting cells for high-resolution immune monitoring" 35 : 977-982, 2017
• 20 Hoogenboom, H. R, "Selecting and screening recombinant antibody libraries" 23 : 1105-1116, 2005
• 21 Starr, C. G, "Selecting and engineering monoclonal antibodies with drug-like specificity" 60 : 119-127, 2019
• 22 Domachowske, J. B, "Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion Ftargeting monoclonal antibody administered as a single dose to healthy preterm infants" 37 : 886-892, 2018
• 23 Dahal, L. N, "STING activation reverses lymphoma-mediated resistance to antibody immunotherapy" 77 : 3619-3631, 2017
• 24 Braig, F, "Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking" 129 : 100-104, 2017
• 25 Wardemann, H, "Predominant autoantibody production by early human B cell precursors" 301 : 1374-1377, 2003
• 26 Frenzel, A, "Phage displayderived human antibodies in clinical development and therapy" 8 : 1177-1194, 2016
• 27 Richards, J. O, "Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells" 7 : 2517-2527, 2008
• 28 Mimoto, F, "Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant" 5 : 229-236, 2013
• 29 Rouet, R, "Next-generation sequencing of antibody display repertoires" 9 : 118-, 2018
• 30 Matlung, H. L, "Neutrophils kill antibody-opsonized cancer cells by trogoptosis" 23 : 3946-3959, 2018
• 31 Ulrichts, P, "Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans" 128 : 4372-4386, 2018
• 32 Bruhns, P, "Mouse and human FcR effector functions" 68 : 25-51, 2015
• 33 Weiner, L. M, "Monoclonal antibodies: Versatile platforms for cancer immunotherapy" 10 : 317-327, 2010
• 34 Jiwon Lee, "Molecular-level Antibody Repertoire Profiling and Engineering: Implications for Developing Next-generation Diagnostics, Therapeutics, and Vaccines" 한국생물공학회 24 (24): 8-11, 2019
• 35 Boross, P, "Mechanisms of action of CD20 antibodies" 2 : 676-690, 2012
• 36 Golay, J, "Mechanism of action of therapeutic monoclonal antibodies: Promises and pitfalls of in vitro and in vivo assays" 526 : 146-153, 2012
• 37 Murphy, K, "Janeway’s Immunobiology" W.W. Norton & Company 2016
• 38 Yu, X, "Isotype switching converts anti-CD40 antagonism to agonism to elicit potent antitumor activity" 37 : 850-866, 2020
• 39 White, A. L, "Interaction with FcγRIIB Is critical for the agonistic activity of anti-CD40 monoclonal antibody" 187 : 1754-1763, 2011
• 40 Ghetie, V, "Increasing the serum persistence of an IgG fragment by random mutagenesis" 15 : 637-640, 1997
• 41 Hatjiharissi, E, "Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa158 V/V and V/F polymorphism" 110 : 2561-2564, 2007
• 42 Arlauckas, S. P, "In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy" 9 : 2017
• 43 Jin Young Kim, "In vivo Protein Evolution, Next Generation Protein Engineering Strategy: from Random Approach to Target-specific Approach" 한국생물공학회 24 (24): 85-94, 2019
• 44 Xu, D, "In vitro characterization of five humanized OKT3 effector function variant antibodies" 200 : 16-26, 2000
• 45 Yu, X, "Improving antibody-based cancer therapeutics through glycan engineering" 31 : 151-166, 2017
• 46 Haraya, K, "Improvement of pharmacokinetic properties of therapeutic antibodies by antibody engineering. Drug Metab" 34 : 25-41, 2019
• 47 Lux, A, "Impact of immune complex size and glycosylation on IgG binding to human FcγRs" 190 : 4315-4323, 2013
• 48 Murdaca, G, "Immunogenicity of infliximab and adalimumab" 18 : 343-345, 2019
• 49 Preiner, J, "IgGs are made for walking on bacterial and viral surfaces" 5 : 4394-, 2014
• 50 Kelton, W, "IgGA: A “cross-isotype”engineered human Fc antibody domain that displays both IgGlike and IgA-like effector functions" 21 : 1603-1609, 2014
• 51 An, Z, "IgG2m4, an engineered antibody isotype with reduced Fc function" 1 : 572-579, 2009
• 52 Vidarsson, G, "IgG subclasses and allotypes: From structure to effector functions" 5 : 520-, 2014
• 53 Lee, C. H, "IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions" 18 : 889-898, 2017
• 54 Vaughan, T. J, "Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library" 14 : 309-314, 1996
• 55 Derebe, M. G, "Human IgG subclass cross-species reactivity to mouse and cynomolgus monkey Fcγ receptors" 197 : 1-8, 2018
• 56 Lefranc, M. P, "Human Gm, Km, and Am allotypes and their molecular characterization: A remarkable demonstration of polymorphism" 882 : 635-680, 2012
• 57 Prassler, J, "HuCAL PLATINUM, a synthetic fab library optimized for sequence diversity and superior performance in mammalian expression systems" 413 : 261-278, 2011
• 58 Biburger, M, "How immunoglobulin G antibodies kill target cells: Revisiting an old paradigm" 124 : 67-94, 2014
• 59 Gérard, A, "High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics" 38 : 715-721, 2020
• 60 Shields, R. L, "High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR" 76 : 6591-6604, 2001
• 61 Mastrangeli, R, "Glycoengineered antibodies: towards the next-generation of immunotherapeutics" 29 : 199-210, 2019
• 62 Genmab, "Global Pipeline"
• 63 Kwakkenbos, M. J, "Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming" 16 : 123-128, 2010
• 64 Gerdes, C. A, "GA201(RG7160): A novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab" 19 : 1126-1138, 2013
• 65 Zhang, D, "Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization" 9 : 1129-1142, 2017
• 66 Wang, B, "Functional interrogation and mining of natively paired human VH:VL antibody repertoires" 36 : 152-155, 2018
• 67 Jakobovits, A, "From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice" 25 : 1134-1143, 2007
• 68 de Taeye, S. W, "FcγR binding and ADCC activity of human IgG allotypes" 11 : 740-, 2020
• 69 Nimmerjahn, F, "Fcγ receptors as regulators of immune responses" 8 : 34-47, 2008
• 70 Stavenhagen, J. B, "Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcγreceptors" 67 : 8882-8890, 2007
• 71 Chen, X, "FCγR-binding is an important functional attribute for immune checkpoint antibodies in cancer immunotheraphy" 10 : 292-, 2019
• 72 Lee, C. H, "Expression of soluble and functional human neonatal Fc receptor in Pichia pastoris" 71 : 42-48, 2010
• 73 Yamane-Ohnuki, N, "Establishment of FUT8 knockout Chinese hamster ovary cells:An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity" 87 : 614-622, 2004
• 74 Zalevsky, J, "Enhanced antibody half-life improves in vivo activity" 28 : 157-159, 2010
• 75 Igawa, T, "Engineering the variable region of therapeutic IgG antibodies" 3 : 243-252, 2011
• 76 Vaccaro, C, "Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels" 23 : 1283-1288, 2005
• 77 Chiu, M. L, "Engineering antibody therapeutics" 38 : 163-173, 2016
• 78 Igawa, T, "Engineered monoclonal antibody with novel antigen-sweeping activity in vivo" 8 : e63236-, 2013
• 79 Lazar, G. A, "Engineered antibody Fc variants with enhanced effector function" 103 : 4005-4010, 2006
• 80 Idusogie, E. E, "Engineered antibodies with increased activity to recruit complement" 166 : 2571-2575, 2001
• 81 Natsume, A, "Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities" 68 : 3863-3872, 2008
• 82 Moore, G. L, "Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions" 2 : 181-189, 2010
• 83 Chen, K, "Endocytosis of soluble immune complexes leads to their clearance by FcγRIIIB but induces neutrophil extracellular traps via FcγRIIA in vivo" 120 : 4421-4431, 2012
• 84 Franchini, M, "Emicizumab for the treatment of haemophilia A: A narrative review" 17 : 223-228, 2019
• 85 Tiller, T, "Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning" 329 : 112-124, 2008
• 86 Sheets, M. D, "Efficient construction of a large nonimmune phage antibody library: The production of high-affinity human single-chain antibodies to protein antigens" 95 : 6157-6162, 1998
• 87 Leabman, M. K, "Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys" 5 : 896-903, 2013
• 88 Jung, S. T, "Effective phagocytosis of low Her2 tumor cell lines with engineered, aglycosylated igg displaying high FcγRIIa affinity and selectivity" 8 : 368-375, 2013
• 89 김성민, "Effect of Environmental Parameters on Glycosylation of Recombinant Immunoglobulin G Produced from Recombinant CHO Cells" 한국생물공학회 23 (23): 456-464, 2018
• 90 . Vaccaro, C, "Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies" 103 : 18709-18714, 2006
• 91 DiLillo, D. J, "Differential Fc-receptor engagement drives an anti-tumor vaccinal effect" 161 : 1035-1045, 2015
• 92 Nelson, A. L, "Development trends for therapeutic antibody fragments" 27 : 331-337, 2009
• 93 E. Dhimolea, "Development trends for human monoclonal antibody therapeutics" 9 : 767-774, 2010
• 94 한겨레, "Design, Synthesis, and Evaluation of Gold Nanoparticle-Antibody- Horseradish Peroxidase Conjugates for Highly Sensitive Chemiluminescence Immunoassay (hs-CLIA)" 한국생물공학회 24 (24): 206-214, 2019
• 95 Strohl, W. R, "Current progress in innovative engineered antibodies" 9 : 86-120, 2018
• 96 Köhler, G., "Continuous cultures of fused cells secreting antibody of predefined specificity" 256 : 495-497, 1975
• 97 백두산, "Construction of a Large Synthetic Human Fab Antibody Library on Yeast Cell Surface by Optimized Yeast Mating" 한국미생물·생명공학회 24 (24): 408-420, 2014
• 98 Goulet, D. R, "Considerations for the design of antibody-based therapeutics" 109 : 74-103, 2020
• 99 Mahajan, S. P, "Computational affinity maturation of camelid single-domain intrabodies against the nonamyloid component of alpha-synuclein" 8 : 17611-, 2018
• 100 Yu, X, "Complex interplay between epitope specificity and isotype dictates the biological activity of anti-human CD40 antibodies" 33 : 664-675, 2018
• 101 Diebolder, C. A, "Complement is activated by IgG hexamers assembled at the cell surface" 343 : 1260-1263, 2014
• 102 Stapleton, N. M, "Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential" 2 : 599-, 2011
• 103 Rimenys Junior Carvalho, "Comparison of Cationic Flocculants for the Clarification of CHO-derived Monoclonal Antibodies" 한국생물공학회 24 (24): 754-760, 2019
• 104 Guglietta, S, "Coagulation induced by C3aR-dependent NETosis drives protumorigenic neutrophils during small intestinal tumorigenesis" 7 : 11037-, 2016
• 105 Teeling, J. L, "Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas" 104 : 1793-1800, 2004
• 106 Yang, Y, "Cancer immunotherapy: Harnessing the immune system to battle cancer" 125 : 3335-3337, 2015
• 107 Yeap, W. H, "CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes" 6 : 34310-, 2016
• 108 Weiner, G. J, "Building better monoclonal antibody-based therapeutics" 15 : 361-370, 2015
• 109 Burt, R, "Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies" 15 : 594-602, 2019
• 110 U.S. National Library of Medicine, "Bispecific mAbs Studies List Results"
• 111 Labrijn, A. F, "Bispecific antibodies: a mechanistic review of the pipeline" 18 : 585-608, 2019
• 112 Lu, L. L, "Beyond binding: Antibody effector functions in infectious diseases" 18 : 46-61, 2018
• 113 Wardemann, H, "B-cell selftolerance in humans" 95 : 83-110, 2007
• 114 Scott, A. M, "Antibody therapy of cancer" 12 : 278-287, 2012
• 115 Wang, W, "Antibody structure, instability, and formulation" 96 : 1-26, 2007
• 116 Igawa, T, "Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization" 28 : 1203-1207, 2010
• 117 Kretschmer, A, "Antibody isotypes for tumor immunotherapy" 44 : 320-326, 2017
• 118 Sampei, Z, "Antibody engineering to generate SKY59, a longacting anti-C5 recycling antibody" 13 : e0209509-, 2018
• 119 Reichert, J. M, "Antibody Fc: Linking adaptive and innate immunity" 6 : 619-621, 2014
• 120 Fujii, I, "Antibody Engineering: Methods and Protocols" Humana Press 345-359, 2004
• 121 Lou, J, "Antibody Engineering" Springer 377-396, 2010
• 122 Cook, E. M, "Antibodies that efficiently form hexamers upon antigen binding can induce complementdependent cytotoxicity under complement-limiting conditions" 197 : 1762-1775, 2016
• 123 Khalil, M, "Anti-CD40 agonist antibodies: Preclinical and clinical experienc" 2 : 61-65, 2007
• 124 Harvey, B. R, "Anchored periplasmic expression, a versatile technology for the isolation of highaffinity antibodies from Escherichia coli-expressed libraries" 101 : 9193-9198, 2004
• 125 Borrok, M. J, "An “Fc-silenced” IgG1 format with extended half-life designed for improved stability" 106 : 1008-1017, 2017
• 126 Kang, T. H, "An engineered human Fc variant with exquisite selectivity for FcγRIIIaV158 reveals that ligation of FcγRIIIa mediates potent antibody dependent cellular phagocytosis with GM-CSF-differentiated macrophages" 10 : 562-, 2019
• 127 Lee, C. H, "An engineered human Fc domain that behaves like a pH-toggle switch for ultra-long circulation persistence. Nat. Commun" 10 : 5031-, 2019
• 128 Vafa, O, "An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations" 65 : 114-126, 2014
• 129 Traggiai, E, "An efficient method to make human monoclonal antibodies from memory B cells: Potent neutralization of SARS coronavirus" 10 : 871-875, 2004
• 130 Coronella, J. A, "Amplification of IgG VH and VL (Fab) from single human plasma cells and B cells" 28 : e85-, 2000
• 131 Jung, S. T, "Aglycosylated IgG variants expressed in bacteria that selectively bind FcγRI potentiate tumor cell killing by monocyte-dendritic cells" 107 : 604-609, 2010
• 132 Schmid, A. S, "Advances in antibody engineering for rheumatic diseases" 15 : 197-207, 2019
• 133 Redpath, S, "Activation of complement by human IgG1 and human IgG3antibodies against the human leucocyte antigen CD52" 93 : 595-600, 1998
• 134 Crosnier, C, "A rapid and scalable method for selecting recombinant mouse monoclonal antibodies" 8 : 76-, 2010
• 135 Lencer, W. I, "A passionate kiss, then run: Exocytosis and recycling of IgG by FcRn" 15 : 5-9, 200
• 136 de Jong, R. N, "A novel platform for the potentiation of therapeutic antibodies based on antigen-dependent formation of IgG hexamers at the cell surface" 14 : e1002344-, 2016
• 137 Love, J. C, "A microengraving method for rapid selection of single cells producing antigen-specific antibodies" 24 : 703-707, 2006